IL296268A - Treatment with powdered intranasal epinephrine - Google Patents
Treatment with powdered intranasal epinephrineInfo
- Publication number
- IL296268A IL296268A IL296268A IL29626822A IL296268A IL 296268 A IL296268 A IL 296268A IL 296268 A IL296268 A IL 296268A IL 29626822 A IL29626822 A IL 29626822A IL 296268 A IL296268 A IL 296268A
- Authority
- IL
- Israel
- Prior art keywords
- epinephrine
- pharmaceutical composition
- particles
- dose
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062989913P | 2020-03-16 | 2020-03-16 | |
| US17/135,528 US11400045B2 (en) | 2020-03-16 | 2020-12-28 | Treatment with powdered intranasal epinephrine |
| PCT/IL2021/050288 WO2021186437A1 (en) | 2020-03-16 | 2021-03-16 | Treatment with powdered intranasal epinephrine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL296268A true IL296268A (en) | 2022-11-01 |
Family
ID=77664091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL296268A IL296268A (en) | 2020-03-16 | 2021-03-16 | Treatment with powdered intranasal epinephrine |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11400045B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4121005A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023517532A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220154709A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115279340A (cg-RX-API-DMAC7.html) |
| AR (1) | AR121593A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021239084A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022018440A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3175130A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL296268A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022011464A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202200119A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021186437A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11400045B2 (en) * | 2020-03-16 | 2022-08-02 | Nasus Pharma Ltd. | Treatment with powdered intranasal epinephrine |
| CN121265577A (zh) | 2020-05-18 | 2026-01-06 | 奥瑞克索股份公司 | 用于药物递送的药物组合物 |
| US12414916B2 (en) | 2021-06-10 | 2025-09-16 | Belhaven BioPharma Inc. | Dry powder formulations of epinephrine and associated methods |
| US11617716B2 (en) | 2021-06-10 | 2023-04-04 | Belhaven BioPharma Inc. | Dry powder formulations of epinephrine and associated methods |
| US12661315B2 (en) | 2021-06-10 | 2026-06-23 | Belhaven BioPharma Inc. | Dry powder formulations of epinephrine and associated methods |
| TW202333658A (zh) | 2021-11-25 | 2023-09-01 | 瑞典商奥瑞克索股份公司 | 包含腎上腺素之新穎醫藥組合物 |
| GB202117016D0 (en) | 2021-11-25 | 2022-01-12 | Orexo Ab | New pharmaceutical device |
| AU2023322235A1 (en) * | 2022-08-11 | 2025-03-13 | De Motu Cordis Pty Ltd | Inhalable epinephrine formulation |
| US12029709B2 (en) | 2022-08-11 | 2024-07-09 | De Motu Cordis Pty Ltd | Inhalable epinephrine formulation |
| KR20260016535A (ko) * | 2023-05-31 | 2026-02-03 | 오렉쏘 에이비 | 아드레날린 수용체 조절제를 포함하는 분무 건조 조성물 |
| US20260108465A1 (en) | 2024-10-21 | 2026-04-23 | Belhaven BioPharma Inc. | Compositions, devices, and methods for intranasal delivery of dry powder epinephrine |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR940006601A (ko) | 1992-09-12 | 1994-04-25 | 야나가와 히로미 | 생리활성 펩티드 조성물 |
| US6017963A (en) | 1995-11-14 | 2000-01-25 | Euro-Celtique, S.A. | Formulation for intranasal administration |
| ATE289825T1 (de) | 1999-04-21 | 2005-03-15 | 1355540 Ontario Inc | Methacoline oder histamine formulierungen zur feststellung von asthma |
| GB2367756B (en) | 2000-10-12 | 2003-01-08 | Bespak Plc | Dispensing apparatus |
| GB2380410B (en) | 2001-10-05 | 2003-11-19 | Alchemy Healthcare Ltd | Apparatus for the nasal or oral delivery of a medicament |
| GB2384190A (en) | 2002-01-22 | 2003-07-23 | Bespak Plc | Dispensing device for a powdered product |
| US20090246281A1 (en) | 2003-11-03 | 2009-10-01 | Norton Healthcare Ltd. | Soft steroid compositions for use in dry powder inhalers |
| WO2006016530A1 (ja) | 2004-08-10 | 2006-02-16 | Translational Research, Ltd. | 速効性でかつ高い吸収性を可能とする経鼻投与用組成物 |
| GB0524194D0 (en) | 2005-11-28 | 2006-01-04 | Univ Aston | Respirable powders |
| EP1960022A1 (en) | 2005-11-29 | 2008-08-27 | Alza Corporation | Nasal delivery device for the delivery of a substance to the olfactory region |
| US20070178166A1 (en) | 2005-12-15 | 2007-08-02 | Acusphere, Inc. | Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration |
| ES2652415T3 (es) * | 2006-12-26 | 2018-02-02 | Shin Nippon Biomedical Laboratories, Ltd. | Preparación para aplicación transnasal |
| GB2448183A (en) | 2007-04-05 | 2008-10-08 | Optinose As | Nasal powder delivery device |
| WO2009050726A2 (en) | 2007-05-28 | 2009-04-23 | Panacea Biotec Limited | Compositions and methods for improved delivery of bupropion |
| RU2491067C2 (ru) | 2007-08-06 | 2013-08-27 | Байотай Терапис, Инк | Способы лечения зависимости |
| US9101539B2 (en) | 2009-05-15 | 2015-08-11 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal pharmaceutical compositions with improved pharmacokinetics |
| CN102166219B (zh) * | 2010-05-25 | 2013-04-17 | 杭州天龙药业有限公司 | 一种鼻腔给药制剂及其应用 |
| WO2012078804A1 (en) | 2010-12-07 | 2012-06-14 | Respira Therapeutics, Inc. | Dry powder inhaler |
| US9949923B2 (en) | 2011-03-15 | 2018-04-24 | Optinose As | Nasal delivery |
| US9789071B2 (en) | 2012-06-27 | 2017-10-17 | G2B Pharma, Inc. | Intranasal formulation of epinephrine for the treatment of anaphylaxis |
| WO2014134070A1 (en) | 2013-02-26 | 2014-09-04 | Baxter International Inc. | Treatment of central nervous system disorders by intranasal administration of immunoglobulin g |
| CN104274426A (zh) | 2013-07-03 | 2015-01-14 | 陆克塞纳医药公司 | 昂丹司琼细粉、昂丹司琼气溶胶组合物及其用途 |
| US20160220489A1 (en) | 2013-09-03 | 2016-08-04 | G2B Pharma Inc. | Intranasal Formulation for the Treatment of Cardiopulmonary Resuscitation (CPR), Cardiac Life Support (CLS), Anaphylaxis and/or Anaphylactoid Reactions |
| CN105979999B (zh) | 2013-12-11 | 2021-03-12 | 株式会社Jms | 阳型连接器 |
| AU2015228541B2 (en) | 2014-03-14 | 2020-09-03 | Opiant Pharmaceuticals, Inc. | Nasal drug products and methods of their use |
| US20200069582A1 (en) | 2014-07-03 | 2020-03-05 | Darren Rubin | Inhalable hemodynamic agents and methods of using the same |
| CN107205938A (zh) * | 2014-12-18 | 2017-09-26 | 温德加普医疗股份有限公司 | 用于溶解或增溶治疗剂的方法和组合物 |
| UA121874C2 (uk) | 2015-02-17 | 2020-08-10 | Елі Ліллі Енд Компані | Порошкова назальна композиція для лікування гіпоглікемії |
| EP3842457A1 (en) | 2015-09-09 | 2021-06-30 | Novartis AG | Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules |
| CA3030359A1 (en) | 2016-08-05 | 2018-02-08 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal pharmaceutical powder compositions |
| CN110996912A (zh) * | 2017-08-20 | 2020-04-10 | 福摩莱克斯医药创新有限公司 | 用于鼻内递送的干粉组合物 |
| US11844859B2 (en) * | 2017-08-20 | 2023-12-19 | Nasus Pharma Ltd. | Dry powder compositions for intranasal delivery |
| ES2791775B2 (es) * | 2018-02-06 | 2023-01-20 | Aegis Therapeutics Llc | Formulaciones de epinefrina intranasal y metodos para el tratamiento de enfermedades |
| KR20200125632A (ko) * | 2018-02-26 | 2020-11-04 | 신 니뽄 바이오메디칼 라보라토리즈, 엘티디. | 분말 제제, 카트리지 및 디바이스 |
| US11400045B2 (en) * | 2020-03-16 | 2022-08-02 | Nasus Pharma Ltd. | Treatment with powdered intranasal epinephrine |
-
2020
- 2020-12-28 US US17/135,528 patent/US11400045B2/en active Active
-
2021
- 2021-03-16 BR BR112022018440A patent/BR112022018440A2/pt unknown
- 2021-03-16 AU AU2021239084A patent/AU2021239084A1/en active Pending
- 2021-03-16 MX MX2022011464A patent/MX2022011464A/es unknown
- 2021-03-16 KR KR1020227033697A patent/KR20220154709A/ko not_active Withdrawn
- 2021-03-16 JP JP2022552858A patent/JP2023517532A/ja active Pending
- 2021-03-16 IL IL296268A patent/IL296268A/en unknown
- 2021-03-16 TW TW110109439A patent/TW202200119A/zh unknown
- 2021-03-16 EP EP21714436.9A patent/EP4121005A1/en active Pending
- 2021-03-16 CN CN202180020993.7A patent/CN115279340A/zh active Pending
- 2021-03-16 CA CA3175130A patent/CA3175130A1/en active Pending
- 2021-03-16 AR ARP210100664A patent/AR121593A1/es unknown
- 2021-03-16 US US17/911,523 patent/US12678402B2/en active Active
- 2021-03-16 WO PCT/IL2021/050288 patent/WO2021186437A1/en not_active Ceased
-
2026
- 2026-02-25 JP JP2026028936A patent/JP2026094260A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021239084A1 (en) | 2022-10-13 |
| US12678402B2 (en) | 2026-07-14 |
| US11400045B2 (en) | 2022-08-02 |
| BR112022018440A2 (pt) | 2022-11-01 |
| US20230105615A1 (en) | 2023-04-06 |
| WO2021186437A1 (en) | 2021-09-23 |
| MX2022011464A (es) | 2022-11-14 |
| EP4121005A1 (en) | 2023-01-25 |
| TW202200119A (zh) | 2022-01-01 |
| AR121593A1 (es) | 2022-06-22 |
| CA3175130A1 (en) | 2021-09-23 |
| KR20220154709A (ko) | 2022-11-22 |
| JP2026094260A (ja) | 2026-06-09 |
| US20210283050A1 (en) | 2021-09-16 |
| CN115279340A (zh) | 2022-11-01 |
| JP2023517532A (ja) | 2023-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11400045B2 (en) | Treatment with powdered intranasal epinephrine | |
| JP7621220B2 (ja) | 疾患の処置のための鼻腔内エピネフリン製剤及び方法 | |
| Fonseca et al. | Intranasal drug delivery for treatment of Alzheimer’s disease | |
| US11331270B2 (en) | Dry powder compositions for intranasal delivery | |
| CN101653414B (zh) | 多西他赛长循环固体脂质纳米粒及其制备方法 | |
| AU2021254650B2 (en) | Intranasal epinephrine formulations and methods for the treatment of disease | |
| JP7312523B2 (ja) | フルベストラント配合物およびその使用方法 | |
| IL260509B1 (en) | Encapsulation of lipophilic components in spray-dried, dispersible powders suitable for inhalation | |
| NZ555501A (en) | Compositions comprising azelastine and methods of use thereof | |
| KR20120034631A (ko) | 지속형 무스카린 안타고니스트 및 지속형 b₂아드레날린 수용체 아고니스트의 폐 전달용 조성물, 및 연관된 방법 및 시스템 | |
| KR20170095807A (ko) | 폐 고혈압의 치료를 위한 흡입가능 라파마이신 제제 | |
| JP2025522774A (ja) | 吸入用被覆結晶形態乾燥粉末の乾燥粉末吸入器用医薬組成物 | |
| WO2021195580A1 (en) | Prevention and treatment of coronavirus-associated diseases using an apelin peptide and formulations thereof | |
| IL318920A (en) | Inhalation preparation containing epinephrine | |
| CN113038930A (zh) | 冻干形式的药物组合物 | |
| KR19990021931A (ko) | 미세구형 전분의 항편두통 조성물 | |
| US20230145276A1 (en) | Aerosolized formulations of an apelin peptide and uses thereof | |
| Patel | Microencapsulated human albumin nanoparticles for drug delivery to the lungs | |
| HK40018410A (en) | Intranasal epinephrine formulations and methods for the treatment of disease | |
| Verma et al. | DEVELOPMENTOFTHEDRY POWDER INHALER: A REVIEW |